The filing is to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC), and has also been granted Priority Review, a designation given to those applications for drugs that, if approved, may offer significant improvements in the safety or effectiveness of the treatment, diagnosis or
One in seven five-year-olds don’t have MMR jabs
Parents of primary school starters are being urged to check their kids’ immunisation records after it was revealed that one in seven five-year-olds may not be fully up to date with some routine immunisations, with the figure rising to around one in four children in London. The ‘worrying’ estimates from
A new report in the British Journal of General Practice has revealed that children prescribed more than two courses of antibiotics within a year for coughs, sore throat and earache are less likely to respond to a subsequent course.
The cohort study, compiled of statistics from the Clinical Practice Research Datalink, identified UK primary care data for children aged one to five years during the period 2009 to 2016, excluding children requiring long-term antibiotic treatment for chronic respiratory diseases such as TB. The analysed data showed that for the 114,329 children who were prescribed
A Shaping Of Pharmaceutical Industry To The Emerging Markets Of The World
As the competitive market has evolved all over world, manufacturers in all industries have been presented with a fundamental challenge with new techniques so they can adjust to a new business environment in an open, forward thinking way to succeed in their business. Today, we can see that the most
Can Jammu & Kashmir build on its pharma base?
Jammu & Kashmir may not be a big market for the Indian pharmaceutical industry, it has a lot to offer to the sector. Industry estimates pharma market size of around Rs 1200-1400 crore in J&K, which may seem big in the absolute figure, but is a fraction of the size
The Health Service Executive (HSE) has granted reimbursement for Pierre Fabre’s Braftovi (encorafenib) and Mektovi (binimetinib) combination in Ireland.
The treatment has been accepted for use on the Irish health service to treat adult patients with unresectable or metastatic melanoma with a mutation in the BRAF V600 gene. The reimbursement means that eligible patients in the Republic of Ireland can potentially benefit from the combination with immediate effect, and